Africa Corporate Wellness Market, by End User, 2018-2027
| Label | USD Million |
|---|---|
| 2018 | 1427.04569002283 USD Million |
| 2019 | 1444.12183389461 USD Million |
| 2020 | 1461.39439012462 USD Million |
| 2021 | 1477.35797393643 USD Million |
| 2022 | 1499.60235089998 USD Million |
| 2023 | 1691.87544038603 USD Million |
| 2024 | 1907.40410669091 USD Million |
| 2025 | 2149.75675310881 USD Million |
| 2026 | 2424.45608919528 USD Million |
| 2027 | 2733.13064207604 USD Million |
| 2028 | 3079.6536388402 USD Million |
| 2029 | 3473.36091696617 USD Million |
| 2030 | 3915.32362419488 USD Million |
| 2031 | 4413.00302489537 USD Million |
| 2032 | 4971.0111608664 USD Million |
Data Source: Wantstats Repository
Market Dynamics
Canada is emerging as a leader in the development and implementation of clinical research on psychedelic drugs, including psilocybin, ketamine, and MDMA. The number of Canadian clinical centers studying psychedelic drugs for mental health has nearly doubled over the past 10 years and more than fifty researchers have been forcibly recruited in the field of psychedelic-assisted therapy in the past two years. In 2018, Canada became the first nation in the world to decriminalize psychedelic mushrooms, allowing for personal possession of up to 30g in the capital city of Vancouver. This move had a domino effect on the state of psychedelic drug use country-wide, as organizations and users across the country have expressed enthusiasm, earnestly looking to capitalize on what they see as an important policy shift. The health benefits ascribed to psychedelic drugs are currently being challenged by Canadian authorities. In 2019, Health Canada's Novel Products Division announced the approval of the country's first clinical trial for the medical use of psychedelic mushrooms, to ‘examine the safety, tolerability, and efficacy of psilocybin in improving the quality of life of individuals suffering from mental illness’.
This novel development has prompted the discussion of the drug's potential to be used in clinical settings. Moreover, public opinion towards the development and use of psychedelic drugs has been largely positive, with researchers pushing to decriminalize psychedelic substances for mental health use in studies. This is largely driven by an influx of social media content discussing the potential of psychedelics to improve mental health; recent surveys have found that1/3 of Canadians have a favourable view toward psychedelics for mental health treatments. The growing acceptance of psychedelic drugs in Canada has created an environment ripe for market growth. An increasing number of companies and entrepreneurs are actively looking for ways to capitalize on Canada's newfound policies. For example, Journe Foods, a Canadian edibles retailer, recently released a series of eight psychedelic mushroom-infused beverages. As more information is gathered, it is likely that the demand for psychedelic drugs in Canada will continue to accelerate over the course of the next decade. We can expect to see new policies governing clinical research, as well as novel methods of marketing and selling psychedelic products.
With so much room for further exploration, it is clear that Canada is primed to be a pivotal player in the future of psychedelic drug use.
Research Methodology
Figures reflect Wantstats’ original market research and forecasting models, compiled as part of the Wantstats research archive and published in 2023.
Unlock the Full Data
Get This Chart
Access the complete chart and underlying data to support your research, analysis, and business decisions.
Powering the world's best teams.
From next-gen startups to established enterprises.
Get in Touch
Let's work together
support@wantstats.comSee our work in action
Start your data driven journey with us!
What our clients say
Trusted by forward-thinking businesses
for data-driven intelligence



